PDF《蓝玉簪颗粒对大鼠肝纤维化的治疗作用》

www.

wjgnet.com [email protected] 世界华人消化杂志 2009年1月8日;

17(1): 11-16 ISSN 1009-3079 CN 14-1260/R 基础研究 BASIC RESEARCH 蓝玉簪颗粒对大鼠肝纤维化的治疗作用 房志鑫, 李旭波, 刘菁菁, 耿铮, 田琼房志鑫, 李旭波, 刘菁菁, 耿铮, 田琼, 中国人民解放军第四 军医大学药理学教研室 陕西省西安市

710032 房志鑫, 硕士, 主要从事分子药理学研究. 作者贡献分布: 此课题由房志鑫设计;

研究过程由房志鑫, 李旭 波, 耿铮及刘婧婧操作完成;

研究所用新试剂及分析工具由田琼 提供;

数据分析由房志鑫完成;

本论文写作由房志鑫完成. 通讯作者: 田琼, 710032, 陕西省西安市长乐西路17号, 中国人 民解放军第四军医大学药理学教研室. [email protected]

电话: 029-84773701 收稿日期: 2008-10-20 修回日期: 2008-11-18 接受日期: 2008-11-24 在线出版日期: 2009-01-08 Therapeutic effects of Lanyuzan granules on hepatic fibrosis in rats Zhi-Xin Fang, Xu-Bo Li, Jing-Jing Liu, Zheng Geng, Qiong Tian Zhi-Xin Fang, Xu-Bo Li, Jing-Jing Liu, Zheng Geng, Qiong Tian, Department of Pharmacology, the Fourth Mili- tary Medical University of Chinese PLA, Xi'an 710032, Shaanxi Province, China Correspondence to: Qiong Tian, Department of Pharma- cology, the Fourth Military Medical University of Chinese PLA, Xi'an 710032, Shaanxi Province, China. [email protected] Received: 2008-10-20 Revised: 2008-11-18 Accepted: 2008-11-24 Published online: 2009-01-08 Abstract AIM: To explore the curative effects of Lanyuzan granules on hepatic fibrosis in dimethylnitrosamine (DMN)-induced SD rat model and its mechanism. METHODS: Forty-five female SD rats were ran- domly divided into six groups: a control group (n = 5), a model group (n = 8), three treatment groups with different dosage of Lanyuzan gran- ules (n = 8), and a positive control group (n = 8). In the following

30 days, an intraperitoneal injec- tion of dimethylnitrosamine (DMN)

10 mg/kg was performed in five groups every three days, except in the control group. On the thirty-first day, the five indexes of hepatic function, serum concentrations of ALT, AST and ALB, the expres- sions of a-smooth muscle actin (a-SMA) and ma- trix metalloproteinase-2 (MMP-2) were measured. Moreover, pathological changes were observed on liver tissue with HE staining. RESULTS: In liver fibrosis model group, serum concentrations of ALT and AST were significant- ly higher and concentration of ALB was signifi- cantly lower (P < 0.05), while significant increase in a-SMA expression and significant decrease in MMP-2 expression were observed compared with the normal group (182.042 ± 0.658 vs 60.879 ± 0.987;

145.612 ± 4.66 vs 74.824 ± 9.004;

16.078 ± 0.633 vs 28.971 ± 0.443;

161.667 ± 26.766 vs 80.167 ± 10.135;

5.994 ± 1.360 vs 8.270 ± 0.289, all P < 0.05). Decreased ALT and AST serum concentra- tions, significantly increased ALB concentration, lowered a-SMA expression and elevated MMP-2 expression in liver tissue, were observed in Lanyuzan granules treatment group compared with model control group (87.856 ± 8.526, 106.69 ± 0.987, 136.11 ± 0.329 vs 182.042 ± 0.658;

94.208 ± 2.017, 107.602 ± 20.014, 118.847 ± 5.486 vs 145.612 ± 4.66;

23.412 ± 0.775, 19.653 ± 0.775, 18.635 ± 0.221 vs 16.078 ± 0.633;

109.958 ± 3.607, 117.833 ± 6.600, 119.833 ± 6.167 vs 161.667 ± 26.766;

11.610 ± 0.523, 10.367 ± 0.714 vs 5.994 ± 1.360, all P < 0.05). No notable difference was observed between low dosage group and model control group. The pathological observation showed hepatic fibrosis was alleviated markedly. CONCLUSION: Lanyuzan granules may play a part in the alleviation of inflammation and the protection of liver by markedly relieving and inhibiting the formation of hepatic fibrosis in- duced by dimethylnitrosamine. Key Words: Lanyuzan;